TPD52L1 is downregulated in post-chemotherapy ovarian tumors (38) and in recurrent nasopharyngeal cancer after the first course of radiotherapy (39), suggesting that TPD52L1 expression is associated with tumor recurrence and responses to current therapeutic drugs against CRC. Here, TPD52L1 is linked to nasopharyngeal carcinoma.